TG Therapeutics Reports Tuesday With Analysts Already Backing Away From Their Own Estimates

TG Therapeutics (TGTX) reports first-quarter 2026 earnings before market open on May 6, with analysts expecting $0.23 per share—a dramatic turnaround from the $0.03 reported in the same quarter last year. The central question: can this commercial-stage biopharmaceutical company sustain momentum after a volatile earnings track record that has seen massive beats followed by significant misses? With the stock trading at $36.10 and analyst sentiment recently deteriorating, tomorrow's report will test whether TGTX's commercial execution can finally match Wall Street's elevated expectations.

Part 1: Earnings Preview

TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, with its lead product BRIUMVI (ublituximab-xiiy) approved for relapsing forms of multiple sclerosis. The company generates revenue primarily through BRIUMVI sales in the U.S. market.

TGTX reports Q1 2026 earnings on May 6 before market open, with consensus estimates calling for $0.23 per share on revenue of approximately $198.44 million. The company most recently reported $0.14 per share for Q4 2025. Year-over-year, the $0.23 estimate represents a +666.67% increase from the $0.03 reported in Q1 2025, reflecting the company's transition from early commercialization to more mature product sales.

Three key themes define this earnings story:

BRIUMVI Commercial Trajectory: The primary focus is whether BRIUMVI sales can meet the $198.44 million revenue estimate and demonstrate sustainable quarter-over-quarter growth. After reporting $192.57 million in Q4 2025, investors are watching for evidence that the multiple sclerosis franchise can maintain its growth trajectory in an increasingly competitive market. The 64% year-over-year revenue growth estimate suggests analysts expect continued market share gains.

Profitability Consistency: Following Q3 2025's extraordinary $2.43 EPS (driven by a one-time gain) and subsequent misses in Q4 2025 ($0.14 vs. $0.35 estimate) and Q1 2025 ($0.03 vs. $0.18 estimate), investors need to see whether TGTX can deliver predictable, sustainable profitability. The company's pattern of significant estimate misses has created credibility concerns that tomorrow's report must address.

2026 Full-Year Guidance: With analysts projecting $1.32 per share for full-year 2026 (down 52% from 2025's $2.77, which included the Q3 anomaly) and $897.41 million in revenue, management's updated guidance will be critical. The market needs clarity on whether the company can achieve the 86% earnings growth projected for 2027 ($2.45 per share).

Analyst commentary ahead of the release reflects cautious optimism tempered by execution concerns. The consensus maintains a Buy rating with a $44.57 average price target (23% upside from current levels), but recent estimate revisions have trended downward—the Q1 estimate has fallen from $0.33 sixty days ago to $0.23 currently. Six analysts maintain Strong Buy ratings, but one analyst recently downgraded to Strong Sell, contributing to the deteriorated sentiment trend. The focus is squarely on whether management can demonstrate the operational discipline needed to meet guidance consistently.

Part 2: Historical Earnings Performance

TG Therapeutics has established a troubling pattern of earnings volatility over the past four quarters. The company has missed estimates in three of the last four quarters, with particularly severe shortfalls in Q1 2025 (-83.33%), Q2 2025 (-46.87%), and Q4 2025 (-60.00%). The sole exception was Q3 2025's massive beat of +912.50%, which appears to have been driven by a one-time event rather than operational performance, as the company immediately returned to missing estimates the following quarter.

The magnitude of these misses is concerning for investors. In Q1 2025, TGTX reported $0.03 against a $0.18 estimate—an 83% shortfall. Q4 2025 saw another significant miss with $0.14 versus the $0.35 consensus. This pattern suggests either overly optimistic analyst projections or inconsistent operational execution, neither of which inspires confidence heading into tomorrow's report.

The trend reveals a company struggling to deliver predictable results during its commercial ramp. While revenue has grown substantially year-over-year, the inability to translate that growth into consistent bottom-line performance matching expectations has created credibility issues. The Q3 2025 outlier of $2.43—more than ten times the estimate—further complicates the picture, making it difficult to establish a reliable baseline for normalized earnings power.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

TG Therapeutics typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price behavior around TGTX earnings reveals significant volatility, with an average absolute Day 0 move of 12.28% and an average Day 0 range of 14.63%. The stock has demonstrated dramatic swings in both directions—the August 2024 report triggered a 19.58% Day 0 surge, while the August 2025 report produced a 17.99% decline. The most recent report in February 2026 saw a more modest 4.18% gain on Day 0.

Day +1 follow-through has been considerably more muted, averaging 3.44% with a 7.45% range, suggesting most of the price discovery occurs in the immediate reaction session. The May 2025 report stands out as particularly brutal, with a 13.26% Day 0 decline followed by an additional 7.48% drop on Day +1, reflecting severe disappointment with results. Investors should prepare for potential double-digit percentage moves in either direction based on whether the company beats or misses the $0.23 estimate.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.59% expected move through the May 15 expiration (10 days out), with an implied range of $33.00 to $39.20. This is notably lower than TGTX's average historical Day 0 move of 12.28%, suggesting options traders may be underpricing potential volatility or that recent earnings reactions have been less extreme than the longer-term average. The 76.01% average implied volatility reflects elevated uncertainty, but the expected move implies a more contained reaction than history would suggest.

Part 3: What Analysts Are Saying

Analyst sentiment on TG Therapeutics currently stands at 4.00 (Buy) with an average price target of $44.57, implying 23% upside from the current $36.10 price. The consensus is supported by 6 Strong Buy ratings, but the picture is complicated by 1 Hold, 1 Moderate Sell, and 1 Strong Sell rating, indicating meaningful disagreement within the analyst community.

Sentiment has deteriorated over the past month, with the average recommendation declining from 4.22 to 4.00. This shift reflects one analyst moving from Hold to Strong Sell, signaling growing concern about the company's ability to meet expectations. The number of Hold ratings also decreased from 2 to 1, suggesting some analysts are taking more definitive stances rather than remaining neutral.

The price target range is exceptionally wide, spanning from a low of $15.00 to a high of $60.00, underscoring the polarized views on TGTX's prospects. The $15.00 bear case implies 58% downside risk, while the $60.00 bull case suggests 66% upside potential. This divergence reflects fundamental disagreement about whether the company can sustain its commercial momentum and achieve profitability targets, or whether recent execution issues signal deeper operational challenges. The mean target of $44.57 sits closer to the bullish end of the range, but the recent deterioration in sentiment and downward estimate revisions suggest analysts are becoming more cautious heading into the Q1 report.

Part 4: Technical Picture

TG Therapeutics enters earnings with strong technical momentum, as the Barchart Technical Opinion has surged to an 88% Buy signal from just 24% a month ago and 40% last week. This dramatic improvement reflects powerful near-term momentum that has pushed the stock above all key moving averages.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates extremely strong near-term momentum heading into the earnings release
• Medium-term (100% Buy): Equally strong intermediate-term signal confirms the uptrend is well-established across multiple timeframes
• Long-term (50% Buy): Moderate buy signal suggests the longer-term trend is constructive but less emphatic than shorter timeframes

Trend Characteristics: The combination of Good strength and Strongest direction indicates TGTX is in a powerful uptrend with accelerating momentum, creating a technically supportive environment for the earnings report.

The stock is trading at $36.10, positioned above all major moving averages: the 5-day ($34.60), 10-day ($35.48), 20-day ($35.16), 50-day ($32.35), 100-day ($31.17), and 200-day ($31.84). This clean technical setup with the stock above every meaningful average is bullish, though it also means TGTX has less downside support if earnings disappoint. The 50-day average at $32.35 represents the first significant support level, approximately 10% below current prices. The technical picture is decidedly supportive heading into tomorrow's report, but the strong pre-earnings run-up raises the bar for what constitutes a positive surprise—the stock may need to significantly beat the $0.23 estimate to extend gains from these elevated levels.